Evaluation of Safety and Immunogenicity of Ad26.Mos4.HIV and CH505 TF chTrimer Combination in Healthy Adults

NCT06205056 · clinicaltrials.gov ↗

PHASE1

Phase

RECRUITING

Status

78

Enrollment

FED

Sponsor class

Conditions

Human Immunodeficiency Virus

Interventions

BIOLOGICAL: Ad26.Mos4.HIV in CH505 TF chTrimer + ALFQ [Arm 1a]
BIOLOGICAL: CH505 TF chTrimer + ALFQ [Arm 1a]
BIOLOGICAL: Placebo [Arm 1a]
BIOLOGICAL: Ad26.Mos4.HIV in CH505 TF chTrimer +ALFQ [Arm 2a]
BIOLOGICAL: CH505 TF chTrimer +ALFQ [Arm 2a]
BIOLOGICAL: Placebo [Arm 2a]
BIOLOGICAL: CH505 TF chTrimer + ALFQ [Arm 1b]
BIOLOGICAL: Placebo [Arm 1b]
BIOLOGICAL: CH505 TF chTrimer + ALFQ [Arm 2b]
BIOLOGICAL: Placebo [Arm 2b]

Sponsor

U.S. Army Medical Research and Development Command

Collaborators

[object Object]
[object Object]
[object Object]
[object Object]
[object Object]
[object Object]